EPIM-001 / Elpis Biopharma - LARVOL DELTA

Enhancing Anti-Tumor Immune Response and Overcoming Resistance (PEGS 2022) - "We will report the discovery and preclinical studies of EPIM-001, a bispecific IL2/PD-L1 biologics that has demonstrated multiple mechanisms of action and potent anti-tumor activity; EPB-001, a human anti-Siglec15 antibody that reversed immune suppression and inhibited tumor growth. EPIM-001 and EPB-001 could be promising therapeutics for tumors that are non-responding or resistant to immune checkpoint inhibitor treatment."

Immune Modulation • Inflammation • Oncology • IL2 • PD-L1 • SIGLEC15

Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities (AACR 2022) - "Furthermore, in the human breast cancer cell line MDA-MB-231, EPIM-001 showed stronger tumor growth inhibition compared to Keytruda. EPIM-001 is a promising immune modulating drug candidate that selectively activates CD8+ T cells and NK Cells with strong anti-tumor activity and safe profile for both immune checkpoint sensitive and insensitive PD-L1 positive tumors."

Late-breaking abstract • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • CD8 • IL2

Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting (Businesswire) - "EPC-001 showed robust anti-tumor activities in vitro and demonstrated high target specificity with the ability of simultaneous target engagement in solution and on cells...Low dose of EPC-001 exhibited potent anti-tumor activity and persistence with favorable memory CAR-T phenotypes....IND filing for EPIM-001 planned for Q2 2022."

IND • Preclinical • Oncology • Solid Tumor